Image: Courtesy of Penn Medicine
Researchers at the University of Pennsylvania School of Medicine have developed a diagnostic test for COVID-19 made of scalable materials that can deliver results within minutes at a fraction of the cost of other tests.
Called RAPID 1.0 (Real-time Accurate Portable Impedimetric Detection prototype 1.0), the test was developed as an alternative to RT-PCR tests, which require trained laboratory technicians to perform and can take days to get results back, according to the Cleveland Clinic.
The new test uses a screen-printed electrode, which the researchers say can be mass-produced, to detect the virus in nasal-swab or saliva samples. Results are returned within four minutes and can be read on a benchtop instrument or on a smartphone.
Legal Disclaimer
You are responsible for reading, understanding and agreeing to the National Law Review s (NLR’s) and the National Law Forum LLC s Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only. Any legal analysis, legislative updates or other content and links should not be construed as legal or professional advice or a substitute for such advice. No attorney-client or confidential relationship is formed by the transmission of information between you and the National Law Review website or any of the law firms, attorneys or other professionals or organizations who include content on the National Law Review website. If you require legal or professional advice, kindly contact an attorney or other suitable professional advisor.
Search jobs 11-May-2021 CORRECTING and REPLACING Former FDA and NIH Leader Dr. Vicki Seyfert-Margolis Joins Penrose TherapeuTx Scientific Advisory Board
Penrose scientific advisory board includes prominent research and regulatory experts in oncology, immunology and mitochondrial science
ANN ARBOR, Mich. & CHICAGO (BUSINESS WIRE) Please replace the release with the following corrected version due to multiple revisions in the first and third paragraphs, as well as correcting all instances of MyOwnMed to My Own Med, Inc. in the release text and image caption.
The corrected release reads:
FORMER FDA AND NIH LEADER DR. VICKI SEYFERT-MARGOLIS JOINS PENROSE THERAPEUTX SCIENTIFIC ADVISORY BOARD
Penrose scientific advisory board includes prominent research and regulatory experts in oncology, immunology and mitochondrial science
How to Optimize Success in Clinical Trials of Antidepressants
By Paula Jacobsen, Ph.D., and Nick DeMartinis, M.D., Praxis Precision Medicines
This is an exceptionally exciting time to be developing therapies for patients suffering from depressive disorders. Advances in antidepressant pharmacology have led to diverse and promising therapeutic options. However, it is important to acknowledge the challenges of conducting clinical trials for major depressive disorder (MDD).
Chief among these challenges is the sensitivity of clinical trial methodology for demonstration of efficacy in MDD. A meta-analysis of antidepressant programs that included FDA-approved antidepressant clinical trial data from randomized, double-blind, placebo-controlled acute treatment studies conducted between 1995 and 2008 revealed that only 50% were successful despite the inclusion of only studies that evaluated doses in the approved therapeutic range.
Operator
Good afternoon, ladies and gentlemen, and welcome to the Dicerna Pharmaceuticals First Quarter 2021 Earnings Conference Call. As a reminder, this conference call is being recorded at the company s request.
I will now turn the call over to your host, Will Grammig of Stern IR. Please go ahead.
Lauren Stival
Investor Relations
Thank you, operator. Good afternoon, everyone, and thank you for joining us to review Dicerna s first quarter 2021 financial results and operational highlights. For anyone who hasn t yet had a chance to review our results we issued a press release after the close of trading today, which is available under the investors and media tab on our website at dicerna.com.